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Clinical trials commonly use adjudication committees to reﬁne endpoints, but observational research or
genome-wide association studies rarely do. Our goals were to establish deﬁnitions of cause-speciﬁc death
after unrelated-donor allogeneic hematopoietic cell transplantation (URD-HCT), to estimate discordance
between reported and adjudicated cause-speciﬁc death, and to identify factors contributing to inconsistency
in cause-speciﬁc death determination. A consensus panel adjudicated cause-speciﬁc death in 1484 patients
who died within 1 year after HCT, derived from 3532 acute leukemia or myelodysplasia patients after
URD-HCT from 2000 to 2011 reported by 151 US transplant centers to the Center for International Blood and
Marrow Transplant Research. Deaths were classiﬁed as disease-related or transplant-related. The panel
agreed with >99% of deaths reported by centers as disease-related and 80% reported as transplant-related.
Year of transplant (cohort effect) and disease status signiﬁcantly inﬂuenced agreement between the panel
and centers. Sensitivity analysis of deaths < 100 days post-transplant yielded the lowest agreement between
the panel and centers for myelodysplastic syndrome patients. Standard predeﬁned criteria for adjudicating
cause-speciﬁc death led to consistent application to similar clinical scenarios and clearer delineation of cause-
speciﬁc death categories. Other studies of competing events such as cancer-speciﬁc versus treatment-related
mortality would beneﬁt from our results. Our detailed algorithm should result in more consistent reporting of
cause-speciﬁc death by centers.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic cell transplantation (HCT) of-
fers the only curative therapy for some hematologic malig-
nancy/disorder patients but has a 1-year post-HCT mortality
rate exceeding 30% [1]. Allogeneic HCT can precipitate adgments on page 1685.
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ty for Blood and Marrow Transplantation.multifactorial cascade of events, the sequence and severity of
which differs between patients. Not all patients who die after
HCT experience all potential post-HCT events. Moreover,
surviving patients may experience a similar sequence of
events as those who did not survive. Patients’ clinical courses
can signiﬁcantly differ across and within cause-speciﬁc
mortality. Additionally, comorbidities carry their own risks
and are difﬁcult to discern fromHCT-speciﬁc causes of death.
As an example, a patient with moderate (not severe)
graft-versus host disease (GVHD) treated with multiple sys-
temic immunosuppressive agents develops an infection and
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causes are not easily delineated, leading to ambiguity of
whether GVHD or infection should be reported as the
primary cause-speciﬁc death. Patients with severe GVHD,
requiring prolonged immunosuppressionmight die of severe
GVHD without infection. Likewise, patients can die of infec-
tion in the absence of GVHD. Hence, GVHD and infection are
not always concurrent causes of death. Discerning the
initiating and contributing cause-speciﬁc deaths is critical in
HCT patients who often have competing and correlated
outcomes.
Endpoint assessment committees are often used to
determine clinical trial endpoints [2,3] but are rarely used for
observational research. The only published study investi-
gating cause-speciﬁc death (GVHD, infection, disease, other)
within the ﬁrst year post-HCT used the primary cause of
death reported by the transplant center [4]. Two additional
studies examined cause-speciﬁc death in HCT patients who
had survived beyond 2 and 5 years post-HCT [5,6]. The ﬁrst
study deﬁned outcomes (death due to disease recurrence,
GVHD, or infection) but did not review or adjudicate indi-
vidual cases [5], whereas the second study used cause of
death reported per the National Death Index in addition to
review of medical data for individual cases [6]. These
methods work for landmark analyses or observational
studies that describe changes over time, but genetic studies
investigating cause-speciﬁc deaths that are incorrectly or
inconsistently assigned could result in biased estimation of
the association between genetic variants and each cause [7].
In preparation for a genome-wide association study
(GWAS) of cause-speciﬁc mortality after unrelated donor
(URD) allogeneic HCT, we convened a consensus panel
to review and adjudicate cause-speciﬁc deaths to reduce
endpoint misclassiﬁcation and subsequent over- or
underestimation of genetic effects. Our ongoing GWAS,
named DISCOVeRY-BMT (Determining the Inﬂuence of
Susceptibility-COnveying Variants Related to 1-Year mortal-
ity after unrelated-donor Blood and Marrow Transplant) is
designed to investigate donor and recipient genetic factors
that contribute to 1-year cause-speciﬁc mortality after URD-
HCT. We report our cause-speciﬁc death deﬁnitions, process
for adjudication, and degree of concordance between the
causes of death reported by individual transplant centers and
the consensus panel.
METHODS
Research Ethics
All patients and donors provided written informed consent for their
clinical data to be used for research purposes and were not compensated for
their participation. This study was reviewed and approved by the Roswell
Park Cancer Institute Institutional Review Board. All patient data were dei-
dentiﬁed. Summary data are provided in this article with the exception of
Supplemental Tables 4 and 5, which contain patient-speciﬁc data that have
been altered slightly to further protect patient identity and conﬁdentiality.
Study Population
Two independent cohorts were studied to determine the consistency of
adjudication results. These cohorts were deﬁned as a training and validation
cohort for the main GWAS.
Cohort 1 included 2609 10/10 HLA-matched, ﬁrst, T cellereplete
URD-HCT recipients treated with myeloablative or reduced-intensity con-
ditioning regimens from 2000 to 2008 for acute myeloid or lymphoblastic
leukemia (AML, ALL) or myelodysplastic syndrome (MDS) who were re-
ported to the Center for International Blood and Marrow Transplant
Research (CIBMTR) and had banked biorepository samples from recipient
and donor [8]. Of 2609 patients, 1116 (43%) died within 1-year after HCT.
Cohort 2 included 572 patients who had a URD-HCT between 2009 and
2011 who otherwise met the same criteria as Cohort 1, together with 351
patients who were 8/8 HLA-matched URD-HCT between 2000 and 2011 butotherwise met the same criteria as Cohort 1. Of 923 patients in Cohort 2, 368
(40%) died within 1 year after HCT.
Patient data and recipientedonor blood samples were contributed by
151 transplant centers. Procedures for the completion and review of CIBMTR
data collection forms, as well as cause(s) of death, differ by transplant center.
The goal of adjudication was to reduce variability in ascertaining the cause-
speciﬁc deaths in patients with similar sequences of events leading to death.Cause of Death Adjudication
The consensus panel consisted of 2 adult HCT physicians (M.P., P.L.M.), a
pediatric hematologist/oncologist (K.O.), and an HCT clinical epidemiologist
(T.H.). Causes of death and additional action plans (eg, request for clinical
information from the transplant center) were recorded for each case by
an independent coinvestigator (X.Z.) using prespeciﬁed nomenclature and
notation. Adjudication of Cohort 1 was completed over 8 months via
3 in-person meetings at the CIBMTR (Milwaukee, WI) and weekly telecon-
ferences. Adjudication for Cohort 2 was completed over 2 days via an
in-person session at the CIBMTR.
Case report form summaries were provided to the consensus panel and
included detailed data summarized in Supplemental Table 1. Each clinical
summary was discussed by the consensus panel using information available
in submitted forms, autopsy reports, error correction forms, and source
documents. Discussions continued until a unanimous consensus was
reached regarding the causes of death or whether additional information
was needed from the transplant center. When additional information was
needed before adjudicating cause-speciﬁc death, up to 3 data queries
requesting source documentation or forms data clariﬁcationwere submitted
to the transplant center.Cause of Death Category Deﬁnitions
The primary cause of death was broadly deﬁned as “disease-related
mortality” (DRM; related to leukemia/MDS relapse/progression, including
death due to toxicity or infection from post-HCT antileukemic therapy) or
“transplant-related mortality” (TRM; any cause of death not included in
DRM), similar to previous HCT studies [3-6]. TRM subtypes were further
classiﬁed as GVHD, infection, organ failure, and other. Cause-speciﬁc deaths
were categorized in a hierarchical manner: disease, GVHD, infection, organ
failure, and then other, in descending priority.
Table 1 provides detailed deﬁnitions and description of clinical sce-
narios. Brieﬂy, DRM included documented post-HCT disease progression,
relapse, or death before day þ30 post-HCT in patients with a high disease
burden pretransplant. Autopsy-conﬁrming presence of disease was coded as
DRM. Treatments such as reinduction chemotherapy, donor lymphocyte
infusion, and second HCT after the index HCT may have caused “TRM-like”
deaths but were coded as DRM because of the hierarchical structure and
priority for the cause-speciﬁc death deﬁnitions.
GVHD deaths included severe acute or chronic GVHD with active
treatment at time of death. Infection deaths included bacterial, viral, fungal,
and/or protozoan infections causing end organ damage. Organ failure deaths
were deﬁned as transplant-related toxicity not due to disease progression,
GVHD, or infection and included, for example, veno-occlusive disease/si-
nusoidal obstructive syndrome, noninfectious interstitial pneumonitis,
adult respiratory distress syndrome, myocardial infarction, and renal failure
in the absence of infection and GVHD. “Other” causes of death included rare
events: vascular events including hemorrhage or thrombosis (eg, pulmo-
nary emboli, stroke), secondary malignancies, primary or secondary graft
failure, accident, suicide, or unknown.
The consensus panel could include an unlimited number of secondary or
contributing causes of death. Based on the hierarchical nature of the deﬁ-
nitions, secondary causes were included only for TRM andwere coded in the
same categories as the primary cause (GVHD, infection, organ failure, other).
Secondary causes contributed to death but were not as severe as the primary
cause or were closer to the time of death. Rare exceptions (affecting3 cases
per category) to the rules were allowed for unusual patient circumstances.Internal and External Validity
Internal validity was tested using 2 approaches [9]. First, 11 sequential
cases from Cohort 1 were blindly re-reviewed 2 months later. Second, 25
nonsequential cases were randomly selected by a nonepanel member (X.Z.)
and blindly re-reviewed by the consensus panel after all cases were
adjudicated.
External validity was measured using a fourth in-person meeting at the
CIBMTR with 2 adult HCT physicians not involved in the study (J.A.H., P.J.M.).
Twenty-one previously adjudicated simple and complex cases from Cohort 1
were selected by a consensus panel member (T.H.) and then adjudicated in
the same manner as prior panel meetings.
Table 1
Deﬁnition of Clinical Scenarios for Adjudication of Primary and Secondary Causes of Death
Primary
Cause-speciﬁc
Death
Secondary
Cause-speciﬁc
Death
Deﬁnition of Clinical Scenarios
Disease None 1. Documented disease progression (if not in CR pre-HCT) or relapse (if in CR pre-HCT) after HCT,
includes evidence of disease on autopsy only.
2. Patient was not in CR pre-HCT and had a high disease burden (ie, >50% blasts in BM or PB pre-HCT)
with no disease evaluation post-HCT and died before day þ100.
GVHD None 1. Severe grades III-IV acute GVHD on active treatment with no infections, no organ toxicity,
no evidence of disease progression or relapse post-HCT, regardless of disease status pre-HCT.
2. Severe chronic GVHD on active treatment involving only lung or only GI or multiple organs,
refractory to immunosuppressive treatment (>3 lines of therapy), no infections, no organ toxicity,
no evidence of disease progression or relapse post-HCT, regardless of disease status pre-HCT.
Infection None 1. Documented infection causing death with no disease progression or relapse, GVHD, or organ toxicity
post-HCT. Infection leading to sepsis and multiorgan failure should be coded in this category.
2. Documented infection causing death, with a history of acute or chronic GVHD or organ failure that
had resolved and was not being treated at the time of diagnosis of the infection. Infection leading
to sepsis and multiorgan failure should be coded in this category.
Organ failure None 1. Severe VOD/SOS, acute renal failure requiring dialysis, uncontrolled seizures, cardiac arrest,
ARDS/IP, or other organ toxicity with maximum acute GVHD grades 0-I or limited mild chronic
GVHD, no serious infections within 2 months of death, no disease progression or relapse post-HCT.
2. Organ failure after successful treatment of prior acute GVHD grades I-III or mild-moderate chronic
GVHD, with resolution of GVHD symptoms and discontinuation of systemic immunosuppression
before organ failure onset date.
Other None 1. Other cause of death in the absence of disease progression/relapse post-HCT, GVHD, infection,
or organ failure. Other causes includes primary or secondary graft failure, thrombotic or
hemorrhagic events, second malignancies, accident, suicide, unknown.
GVHD Infection 1. Acute GVHD grades III-IV or extensive severe chronic GVHD on active treatment with a documented
infection contributing to death; GVHD was severe enough to cause death even if infection did not
occur; no evidence of disease progression or relapse post-HCT, no organ toxicity post-HCT.
GVHD Infection,
organ failure
1. Acute GVHD grades III-IV or extensive severe chronic GVHD on active treatment with a documented
infection and organ toxicity both contributing to death; GVHD was severe enough to cause death even
if infection and organ toxicity did not occur; no evidence of disease progression or relapse post-HCT.
GVHD Organ failure 1. Acute GVHD grades III-IV or extensive severe chronic GVHD on active treatment with a proximal
serious organ failure in a non-GVHD organ (ie, heart, CNS, pancreas) that contributed to death,
and no evidence of disease progression or relapse post-HCT, no infections.
GVHD Other 1. Acute GVHD grades III-IV or extensive severe chronic GVHD on active treatment with an “other”
contributing cause such as TTP/HUS, pulmonary emboli, hemorrhage in an organ not affected by GVHD,
and with no evidence of disease progression or relapse post-HCT, no infections, no organ toxicity.
Infection GVHD 1. Documented infection severe enough to cause death (ie, fungal or viral pneumonia,
bacteremia/sepsis, disseminated infection, toxoplasmosis, etc.) in the setting of acute GVHD
maximum grades II-III or mild to moderate chronic GVHD on active treatment; GVHD contributed
to death, was actively being treated at time of death, but was not severe enough to cause death
without the infection.
Infection Other 1. Documented infection causing death with an “other” contributing cause such as TTP/HUS, pulmonary
emboli, hemorrhage in an organ not affected by GVHD, and with no evidence of disease progression
or relapse post-HCT, no GVHD, no organ toxicity.
Other Infection 1. An “other” cause, such as TTP/HUS or hemorrhage or pulmonary emboli, that was severe enough
to be fatal, along with a documented infection(s) that contributed to death, and no evidence
of disease progression or relapse post-HCT, no GVHD, or resolution of GVHD symptoms
and discontinued systemic immunosuppression.
Other Organ failure 1. An “other” cause, such as TTP/HUS or hemorrhage or pulmonary emboli, that was severe enough to
be fatal, along with severe organ failure that contributed to death, and no evidence of disease
progression or relapse post-HCT, no GVHD, or resolution of GVHD symptoms and discontinued
systemic immunosuppression.
CR indicates complete remission; BM, bone marrow; PB, peripheral blood; GI, gastrointestinal tract; VOD/SOS, veno-occlusive disease/sinusoidal obstructive
syndrome; ARDS/IP, adult respiratory distress syndrome/interstitial pneumonitis; CNS, central nervous system; TTP/HUS, thrombotic thrombocytopenic
purpura/hemolytic uremic syndrome.
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A ﬁrst-order agreement coefﬁcient (AC1) was used to assess transplant
centereconsensus panel agreement. As with Cohen’s kappa statistic, AC1
values range from 0 to 1 with a higher value indicating greater concordance
[10,11]. The kappa statistic was not used as the primary agreement measure
because of the unblinded nature of the consensus panel review [10,12,13]
and the disproportionate prevalence of the competing causes of death
[11,14-16]. AC1 conﬁdence intervals were taken from the .025 and .975
quantiles of the bootstrapped AC1 distribution (n ¼ 10,000) of the observed
transplant centereconsensus panel cause-speciﬁc death contingency table
[17]. A bias index was calculated to demonstrate the proportion of the total
sample that moved into (positive value) or out of (negative value) a cause-
speciﬁc death category [14,18], and a prevalence index was used to mea-
sure the proportion of all cases in each transplant centereconsensus panel
agreement cell [12,14].
Several analyses were performed to measure the association with and
dependencies between covariates and transplant centereconsensus panelagreement on primary cause-speciﬁc deaths. Logistic regression models
were used to test for patient characteristics associated with transplant
centereconsensus panel agreement on broad categories of death (DRM
versus TRM) and speciﬁc TRM categories (GVHD, organ failure, infection).
Quasi-symmetric log-linear models were constructed to assess de-
pendencies of each covariate with transplant centereconsensus panel
agreement on cause-speciﬁc death [19-21]. Covariates tested include
recipient gender and age, year of transplant, disease (AML, ALL, MDS), and
disease status (early, intermediate, advanced). All statistical analyses were
performed using R statistical software [22].RESULTS
Demographics
Patient, disease, and treatment characteristics are shown
in Table 2 for both cohorts. Cohort 2 was older and heavier
Table 2
Recipient Characteristics of the First and Second Cohorts
Recipient Characteristics First Cohort
(n ¼ 2609)
Second Cohort
(n ¼ 923)
P
Age, yr .002
40 1528 (59%) 594 (64%)
<40 1081 (41%) 329 (36%)
Male 1475 (57%) 504 (55%) NS
Race NS
White 2442 (94%) 867 (94%)
Non-white 114 (4%) 44 (5%)
Missing/unknown 53 (2%) 12 (1%)
Disease <.001
AML 1535 (59%) 572 (62%)
ALL 653 (25%) 124 (13%)
MDS 421 (16%) 227 (25%)
AML disease status <.001
Early 677 (44%) 310 (54%)
Intermediate 386 (25%) 121 (21%)
Advanced 472 (31%) 141 (25%)
ALL disease status NS
Early 248 (38%) 57 (50%)
Intermediate 278 (43%) 42 (30%)
Advanced 127 (19%) 25 (20%)
MDS disease status <.001
Early 277 (75%) 83 (37%)
Intermediate d d
Advanced 144 (25%) 144 (63%)
KPS/LPS NS
90-100 1816 (70%) 585 (63%)
80 786 (30%) 286 (31%)
Missing 7 (<1%) 52 (6%)
Year of HCT d
2000-2002 450 (17%) 33 (4%)
2003-2005 926 (35%) 90 (9%)
2006-2008 1233 (47%) 121 (13%)
2009-2011 0 679 (74%)
BMIy .011
Underweight 50 (2%) 25 (3%)
Normal 977 (37%) 293 (32%)
Overweight 811 (31%) 310 (34%)
Obese 764 (29%) 295 (32%)
Missing 7 (<1%) 0
Graft source <.001
Peripheral blood 1648 (63%) 660 (72%)
Bone marrow 961 (37%) 263 (28%)
NS indicates not signiﬁcant (P > .1); Early, AML/ALL in ﬁrst CR or MDS re-
fractory anemia with or without ringed sideroblasts; Intermediate, AML/ALL
in second or greater CR; Advanced, AML/ALL not in remission or MDS re-
fractory anemia with excess blasts; KPS, Karnofsky performance score; LPS,
Lansky performance score, BMI, body mass index.
y BMI deﬁnitions for 18 years: underweight <18, normal 18 to <25,
overweight 25 to <30, obese  30 mg/kg2; BMI for 2 and <18 years:
underweight <5th percentile, normal 5 to <85th percentile, overweight
85 to<95th percentile, obese 95th percentile; BMI for<2 years coded as
normal [23].
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disease and less with ALL, and more peripheral blood grafts.
Other characteristics were well balanced between the
cohorts, with the exception of the planned differences in year
of HCT based on the cohort ascertainment.
Data Queries and Resolutions
The consensus panel identiﬁed 99 of 1484 cases (6.7%) as
needing additional information from the transplant center to
determine the causes of death. Transplant center responses
were received for 76 of 99 data queries (77%), and cause-
speciﬁc death was resolved by the consensus panel for all
76 cases. The remaining 23 cases with no response from the
transplant center were re-reviewed by the consensus panel
for ﬁnal resolution of cause-speciﬁc death.Internal and External Validity
All measures of internal and external validity showed
excellent concordance for both primary and secondary
cause-speciﬁc death. The 11 sequential cases demonstrated
100% agreement between ﬁrst and second review, and the
randomly selected 25 cases were 95% concordant on primary
and secondary cause-speciﬁc death, including their order.
External reviewers were in 100% agreement on all 21 pre-
viously adjudicated cases.
Primary Cause of Death: DRM versus TRM
For Cohort 1, the primary cause-speciﬁc death categorized
as DRM versus TRM demonstrated 87.5% agreement between
the transplant center and consensus panel (AC1 ¼ .75; 95%
conﬁdence interval [CI], .73 to .80), and the bias index was
.12. The consensus panel agreed with 463 of 465 cases (99.6%
agreement) reported by the transplant center as DRM and
with 521 of 651 cases (80% agreement) reported by the
transplant center as TRM. The consensus panel adjudicated
the remaining 130 cases as DRM instead of TRM.
For Cohort 2, similar results demonstrated an overall
agreement of 89% (AC1 ¼ .78; 95% CI, .71 to 0.84). The
consensus panel agreed with 162 of 164 cases (98.8%)
reported by the transplant center as DRM and with 165 of
204 cases (81%) for TRM. The bias index was .10, indicating
little difference in results of TRM or DRM adjudication
between the 2 cohorts.
Primary Cause of Death: Disease versus GVHD versus
Infection versus Organ Failure versus Other
Table 3 summarizes the transplant centereconsensus
panel agreement on DRM, GVHD, infection, organ failure, and
other cause-speciﬁc death categories after adjudicating the
primary causes of death for Cohorts 1 and 2, whereas Figure 1
graphically summarizes the same information for both cohorts
combined. Supplemental Table 2 expresses the reclassiﬁcation
by the consensus panel in percentages, and Supplemental
Table 3 shows the statistical measures of agreement. The
overall agreement for Cohort 1 considering all 5 cause-speciﬁc
death categories was 73% (AC1 ¼ .67; 95% CI, .64 to .70). The
consensus panel agreed with the transplant center 80% and
99% for GVHD and disease deaths, respectively, with most
discordance in cases reportedby the transplant centerasorgan
failure or other (Table 3, Supplemental Table 2, and Figure 1).
Of the 220 cases reported by the transplant center as organ
failure, 115 (52%) were reclassiﬁed by the consensus panel as
disease (mainly organ failure due to additional therapy for
post-HCT relapse), GVHD (which led to multiorgan failure),
infection (which led to sepsis/multiorgan failure), or other
(Table 3, Figure 1). For the 113 cases reported by the transplant
center as other cause-speciﬁc death, the consensus panel was
able to classify 75 of them (67%) into a more speciﬁc category
(Table 3, Supplemental Tables 2 and 3, Figure 1).
Similarly, Cohort 2 had an overall agreement of 70%
(AC1 ¼ .64; 95% CI, .58 to .69), with 68% of other and 72% of
organ failure deaths reported by the transplant center cate-
gorized by the consensus panel into a different category
(Table 3), and again the consensus panel agreed with 91% to
99% of transplant center cause-speciﬁc deaths for GVHD and
disease. Additional agreement statistics are summarized in
Supplemental Tables 2 and 3.
All Contributing Causes of Death
Table 4 summarizes the transplant centereconsensus
panel agreement for all cause-speciﬁc deaths for Cohorts 1
Table 3
Distribution of the Most Common Categories of Primary Cause of DeathWithin 1 Year after Transplant, Reported by the Transplant Center vs. Adjudicated by the
Consensus Panel
Consensus Panel: Cohort 1 N (%) Agreement
Primary Cause-speciﬁc Death Disease GVHD Infection Organ Failure Other
Transplant Center Disease 463 0 0 2 0 465 (99.6%)
GVHD 16 105 8 3 0 132 (79.5%)
Infection 44 24 101 12 5 186 (54.3%)
Organ failure 45 31 27 105 12 220 (47.8%)
Other 25 13 16 21 38 113 (33.6%)
N (%) Agreement 593 (78.1%) 173 (60.7%) 152 (66.4%) 143 (73.4%) 55 (69.1%) 1116
Consensus Panel: Cohort 2 N (%) Agreement
Primary Cause-speciﬁc Death Disease GVHD Infection Organ Failure Other
Transplant Center Disease 162 0 1 1 0 164 (98.8%)
GVHD 3 38 0 0 1 42 (90.5%)
Infection 9 20 29 6 2 66 (43.9%)
Organ failure 13 13 8 16 8 58 (27.6%)
Other 14 4 1 7 12 38 (31.6%)
N (%) Agreement 201 (80.6%) 75 (50.7%) 39 (74.4%) 30 (53.3%) 23 (52.2%) 368
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another cause,” followed by “GVHD and infection, with or
without another cause,” “GVHD without infection, with or
without another cause,” “infection without GVHD, with
or without another cause,” and “organ failure without GVHD
without infection, with or without another cause.” Between
the 2 cohorts, the consensus panel adjudicated 189 deaths
to GVHD and infection ( other contributing causes),
181 deaths to infection without GVHD ( other contributing
causes), and 138 deaths to GVHD without infection ( other
contributing causes). These 3 clinical scenarios occurredwith
similar frequencies. Results between the 2 cohorts were
consistent, despite adjudication schedule differences, inclu-
sion of 8/8 HLA matching in Cohort 2, different years of HCT,
and different patient characteristics (Table 2).
Clinical Scenarios
Supplemental Tables 4 and 5 detail examples of the
adjudication results where the transplant center and
consensus panel disagreed and agreed, respectively. These
examples illustrate the common and rare scenarios that were
adjudicated and provide more information about the de-
cisions made and factors considered during the adjudication.Figure 1. Visual summary of the proportion of causes of death in each category as rep
both cohorts. Black boxes indicate >15% of deaths in that TRM category were reclass
reclassiﬁed, white boxes indicate <5% of deaths in that TRM category were reclassiﬁed,
transplant center.Factors Associated with Transplant Center and Consensus
Panel Agreement
The multivariate models indicated that both the trans-
plant centers and consensus panel coded the causes of death
based on patient disease (AML, ALL, or MDS); hence, the
proportion of transplant centereconsensus panel agreement
did not vary by disease. However, the consensus panel relied
on disease status (in remission or not) to adjudicate cause-
speciﬁc deaths, whereas this was not consistently done by
the transplant centers. This difference, in combination with
the consistent application of cause-speciﬁc death deﬁnitions
by the consensus panel but not the transplant centers,
accounted for most of the transplant centereconsensus
panel discordance. In addition, the transplant center cause-
speciﬁc deaths demonstrated a cohort effect: Agreement
between the transplant center and consensus panel was
lower earlier in the cohort (HCT in 2000 to 2003) compared
with later (HCT in 2009 to 2011).
Assessment of Transplant Center and Consensus Panel
Agreement among Early Deaths
Table 5 summarizes the results of a sensitivity analysis of
transplant centereconsensus panel agreement for bothorted by the transplant center that were reclassiﬁed by the consensus panel for
iﬁed, dotted boxes indicate 5 but <15% of deaths in that TRM category were
and gray boxes indicate the percent agreement of the consensus panel with the
Table 4
Distribution of the Most Common Combinations of Causes of Death Reported by the Transplant Center vs. Adjudicated by the Consensus Panel
Consensus Panel: Cohort 1 N (%)
Agreement
All Causes of Death Disease 
Other
GVHD  Other
(No Infection)
GVHD þ
Infection 
Other
Infection 
Other (No GVHD)
Organ Failure 
Other (No GVHD,
No Infection)
Other (No GVHD,
Infection,
Organ Failure)
Transplant
Center
Disease  other 482 0 0 1 2 1 486 (99%)
GVHD  other (no infection) 14 88 25 1 6 1 135 (65%)
GVHD þ infection  other 7 4 51 1 0 1 64 (80%)
Infection  other (no GVHD) 36 2 40 102 10 2 192 (53%)
Organ failure  other
(no GVHD, no infection)
38 10 10 26 84 3 171 (49%)
Other (no GVHD, infection
or organ failure)
16 7 4 9 11 21 68 (31%)
N (%) Agreement 593 (81%) 111 (79%) 130 (39%) 140 (73%) 113 (74%) 29 (72%) 1116
Consensus Panel: Cohort 2 N (%)
Agreement
All Causes of Death Disease 
Other
GVHD  Other
(No Infection)
GVHD þ
Infection 
Other
Infection 
Other (No GVHD)
Organ Failure 
Other (No GVHD,
No Infection)
Other (No GVHD,
Infection,
Organ Failure)
Transplant
Center
Disease  other 170 0 0 1 1 0 172 (99%)
GVHD  other (no infection) 3 20 14 0 0 0 37 (54%)
GVHD þ infection  other 2 1 20 1 0 0 24 (83%)
Infection  other (no GVHD) 8 3 21 31 2 2 67 (46%)
Organ failure  other
(no GVHD, no infection)
11 2 2 7 14 7 43 (33%)
Other (no GVHD, infection
or organ failure)
7 1 2 1 3 11 25 (44%)
N (%) Agreement 201 (85%) 27 (74%) 59 (34%) 41 (76%) 20 (70%) 20 (55%) 368
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because these were the most difﬁcult to adjudicate. This
analysis demonstrates how transplant centereconsensus
panel agreement is associated with disease status before
URD-HCT. Agreement was highest for early disease statusTable 5
Sensitivity Analysis of Agreement between Reported and Adjudicated Cause-speci
Timing of Death Occurrence after URD-HCT Disease Risk* Rate of Agr
Treatment
Consensus
AML and ALL patients, Cohorts 1 and 2
Days 0-30, 121 deaths (4%) in 2884 patients
Early 26/32 (81
Intermediate 13/24 (54
Advanced 32/65 (49
Days 0-100, 478 deaths (17%) in 2884 patients
Early 110/150 (73
Intermediate 80/108 (74
Advanced 141/220 (64
MDS patients, Cohorts 1 and 2
Days 0-30, 21 deaths (3%) in 648 patients
Early 2/11 (18
Advanced 6/10 (60
Days 0-100, 122 deaths (19%) in 648 patients
Early 39/63 (62
Advanced 35/59 (59
* Disease Risk categories deﬁned as follows: for AML and ALL, early indicated ﬁr
and advanced not in complete remission at URD-HCT; for MDS, early indicated refra
and advanced all other MDS subtypes.AML/ALL deaths before day þ30 post-HCT (81%), followed
by early or intermediate disease AML/ALL deaths before
day þ100 post-HCT (73% to 74%). Agreement was lowest
among early disease risk MDS deaths before day þ30 post-
HCT (18%).ﬁc Death < 100 Days after URD-HCT
eement between
Center and
Panel
Summary of Consensus Panel Changes
%) 6 cases were recoded as a different TRM category
%) 11 cases were recoded as a different TRM category
%) 6 cases were recoded as a different TRM category
27 cases were recoded from TRM to DRM
%) 38 cases were recoded as a different TRM category
3 cases were recoded from TRM to DRM
%) 25 cases were recoded as a different TRM category
3 cases were recoded from TRM to DRM
%) 33 cases were recoded as a different TRM category
46 cases were recoded from TRM to DRM
%) 6 cases were recoded as a different TRM category
3 cases were recoded from TRM to DRM
%) 1 case was recoded as a different TRM category
1 case was recoded from DRM to TRM
2 cases were recoded from TRM to DRM
%) 20 cases were recoded as a different TRM category
4 cases were recoded from TRM to DRM
%) 13 cases were recoded as a different TRM category
9 cases were recoded from DRM to TRM
2 cases were recoded from TRM to DRM
st complete remission, intermediate second or greater complete remission,
ctory anemia with or without ringed sideroblasts or not otherwise speciﬁed
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Based on our ﬁndings, the following groups should be
prioritized for future studies needing adjudication of cause-
speciﬁc death: all MDS patients who died before day þ100
and all patients regardless of disease or disease status whose
cause of death was reported as “other” or “organ failure.”
Although the rate of agreement was higher for AML/ALL
patients in remission pre-HCT and for deaths reported as due
to “GVHD” or “infection,” there was still about a 20% to 27%
discordance between reported and adjudicated death. This
rate of discordance is enough to bias analyses of cause-
speciﬁc mortality, and thus these groups are recommended
for adjudication as well. Based on our report of 99% agree-
ment between reported and adjudicated death, cause of
death reported as recurrence or relapse of disease does not
need to be adjudicated. This represented 42% of all deaths in
our study population.
DISCUSSION
Application of our algorithm to future studies should
focus efforts on adjudication of cases reported as TRM,
particularly infection, organ failure or other, as well as AML
and ALL patients who were not in remission at the time of
HCT and all MDS patients. The current CIBMTR guidance
provided to transplant centers for reporting causes of death
uses the Centers for Disease Control and Prevention and
World Health Organization deﬁnitions for the underlying
cause of death, deﬁned as “the disease or injury that initiated
the chain of events that led directly or inevitably to death”
[24-26]. However, many transplant centers report the last
event in a cascade of multiple events. We deﬁned the cause-
speciﬁc death categories based on the CIBMTR guidance, our
clinical experience, prior publications of similar studies, and
our intent to study genetic contributions to important,
common causes of death. Other investigators studying the
risk factors for these outcomes or evaluating a multistate
modeling approach to deﬁne the risk of 1 phenotype (eg,
infection) after developing another (eg, GVHD) could attri-
bute causes of death with different deﬁnitions, prioritization,
or hierarchy.
Having precise categories of cause-speciﬁc death with
prespeciﬁed deﬁnitions allowed the consensus panel to
categorize most of the “other” cause-speciﬁc death cases into
more speciﬁc categories (GVHD, infection, organ failure,
disease). The ability to attribute more than 1 cause-speciﬁc
death to each case by incorporating both timing and
severity of each outcome allowed better separation of cases
into single versus multifactorial causes of death. For patients
with relapsed disease, the primary cause-speciﬁc death is
deﬁned as disease, even if patients died with complications
including infection, organ failure, or GVHD. This practice is
not uniformly applied in clinical research and varied over
time in the CIBMTR cohort. This lack of uniformity between
centers and over time could be due to changes in data man-
ager education, the real-time reporting of individual cases by
>150 transplant centers over a 12-year period, changes to the
CIBMTR forms over time, availability of medical records
(before/after electronic medical records), or a lack of stan-
dards for how to select and prioritize cause-speciﬁc deaths
when multiple competing serious events occur.
Our consensus panelmethodically adjudicated all deaths in
the DISCOVeRY-BMT study with internal and external validity
controls [9]. There were no validation inconsistencies using
short (2-day) or prolonged (8-month) review. Compact and
prolonged schedules represent feasible designs for futurestudies, as long as quality assurance measures are used. This
study was possible because the investigator team understood
the critical importance of the review process and was dedi-
cated to accuracy and consistency.
This approach to deﬁning cause-speciﬁc death will enable
us to perform a reproducible and accurate evaluation of
genetic variants associated with TRM. We evaluated the
potential impact of endpoint misclassiﬁcation on our future
GWAS study (DISCOVeRY-BMT) using the methods described
by Wray et al. [7] in the context of our adjudication results.
Because 20% of TRM cases reported by the transplant center
were reclassiﬁed as DRM, the estimate of total genetic vari-
ance explained by single nucleotide polymorphisms for TRM
and DRM would decrease by 25% to 33% depending on the
extent to which genetic variants contribute to TRM. There-
fore, if we had not performed the adjudication, the total
amount of true genetic variance contributing to these clinical
endpoints after URD-HCT would have been difﬁcult to assess
and the results subject to confounding by an increased false-
positive discovery rate.
Our ﬁndings are applicable to any GWAS investigating
competing events, such as cancer-speciﬁc mortality versus
treatment-related mortality, especially when multiple cen-
ters contribute data. Adjudication of the primary endpoint in
observational research helps to eliminate potential cohort
effects, reduces outcome heterogeneity, and increases the
likelihood of discovering true genetic associations. Our
detailed and easy to use outcome algorithm (Table 1) pro-
vides the standards and deﬁnitions necessary to yield more
consistent and accurate reporting of cause-speciﬁc death by
participating CIBMTR centers.
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